دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?
Mattia Galli & Dominick J Angiolillo
doi : 10.1080/17512433.2023.2203381
Expert Review of Clinical Pharmacology, Volume 16, Issue 5 (2023)
Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis
Anjay Rastogi, Steven Fishbane & Edgar Lerma
doi : 10.1080/17512433.2023.2197209
Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are ‘moderately’ to ‘extremely bothered’ by itching, associated with reduced quality of life, poor sleep quality, and depression as well as worse clinical outcomes, including increased medication use, infections, hospitalizations, and mortality.
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Gema Ariceta
doi : 10.1080/17512433.2023.2209317
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are two rare and severe conditions caused by chronic complement (C’) system dysregulation.
Perspectives on deprescribing in palliative care
Jennifer Tjia, Maki Karakida, Matthew Alcusky & Jon P Furuno
doi : 10.1080/17512433.2023.2197592
Pharmacotherapy plays a critical role in the delivery of high-quality palliative care, but the intersection of palliative care and deprescribing has received little attention.
Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management
Rosanna Ruggiero, Raffaella Di Napoli, Nunzia Balzano, Donatella Ruggiero, Consiglia Riccardi, Antonietta Anatriello, Andrea Cantone, Liberata Sportiello, Francesco Rossi & Annalisa Capuano
doi : 10.1080/17512433.2023.2211262
Immune checkpoint inhibitors (ICIs) represent an innovative therapeutic approach of oncologic diseases. In Europe, this therapeutic class currently includes eight agents: ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, cemiplimab, durvalumab and dostarlimab. Despite their proved clinical benefits, they can induce immune-related adverse events (irADRs), that can also involve the nervous system.
Provider-directed analgesia for dental pain
Alan L Myers & Arthur H Jeske
doi : 10.1080/17512433.2023.2206118
Extraction of impacted molar teeth is a common procedure performed by oral surgeons and general dentists, with postoperative pain being a significant adverse event post-surgery. If mismanaged, pain can lead to complications that impact oral and systemic health. The current scourge of the opioid epidemic has ushered in a new era of provider-directed analgesic (PDA) therapy in dentistry.
Psychiatric and non-psychiatric drugs causing false-positive amphetamines urine test in psychiatric patients: a pharmacovigilance analysis using FAERS
Vera Battini, Giovanna Cirnigliaro, Luca Giacovelli, Maria Boscacci, Silvia Massara Manzo, Giulia Mosini, Greta Guarnieri, Michele Gringeri, Beatrice Benatti, Emilio Clementi, Bernardo Dell’Osso & Carla Carnovale
doi : 10.1080/17512433.2023.2211261
Immunoassay urine drug screen (UDS) is frequently used in clinical practice for initial screening process, being generally available, fast, and inexpensive. Exposure to widely prescribed drugs might determine false-positive UDS amphetamines, leading to diagnostic issues, wrong therapeutic choices, impairment of physician–patient relationship, and legal implications.
Parametric population pharmacokinetics of isoniazid: a systematic review
Jinmeng Li, Xinjun Cai, Yueting Chen, Chenyu Wang & Zheng Jiao
doi : 10.1080/17512433.2023.2196401
Isoniazid (INH) plays an important role in prevention and treatment of tuberculosis (TB). However, large pharmacokinetic (PK) variations are observed in patients receiving standard INH dosages. Considering the influence of PK variations on INH efficacy or adverse reactions, we reviewed the population PK studies of INH and explored significant covariates that influence INH PK.
